Currently, major pharmaceutical companies are focusing on investigating more targeted approaches to cancer therapy. Cancer R & D is rapidly migrating from traditional cytotoxic chemotherapies toward higher specificity immunological and biological approaches that target unique biochemical receptors and signaling pathways. For 2002-2004, market growth in cancer therapeutics will be dominated by novel agents, such as anti-angiogenics, monoclonal antibodies, topoisomerase inhibitors, and aromatase inhibitors. Any company not heavily invested in these areas will fail to achieve a strong market presence. These new drugs will be more cancer- and patient-specific and will have the potential for slowing cancer growth and inhibiting disease progression, with fewer adverse effects on the patient.

(Photo: )

Outlook for Cancer Therapeutics: An Analysis of Key Competitor Pipelines, a DR Reports publication from Decision Resources, Inc., profiles the emerging therapies in ten leading R&D pipelines. This 142-page report focuses on the four most common types of cancer: lung, colorectal, breast, and prostate. It provides an excellent overview of disease pathophysiology, staging, diagnosis, standard of care, risk factors, and current therapies.

Companies profiled include: Bristol-Myers Squibb, AstraZeneca, Roche, Genentech, Aventis, Pharmacia, Sugen, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, and Ilex Oncology. The report highlights these companies':

  -- Marketed and development-stage drugs   -- Patent position   -- Financial outlook   -- Future promise  

Outlook for Cancer Therapeutics: An Analysis of Key Competitor Pipelines is currently available for $5,250 in print and electronic format.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

   Contact    Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or    In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel),    +81.3.5401.2617 (fax), or 



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636, or

New Report From Decision Resources Evaluates Emerging Therapies to Treat Pancreatic Cancer

View Now